A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer

Conclusions: Anti-PD-1 may be a better choice for patients with metastatic and previously treated NSCLC who failed first-line treatment in terms of the treatment ranking.

Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Wei You, Mei Liu, Ji-Dong Miao, Yu-Qian Liao, Yi-Bing Song, Dian-Kun Cai, Yang Gao, Hao Peng Tags: Research Paper Source Type: research